US$ 20.64
cigna coverage for glp 1 prior authorization Ozempic, Wegovy, Mounjaro & Zepbound Perspectives from employers on the
Description
doi: 10.1111/apha.12220
The use of semaglutide was associated with improved clinical symptoms, physical activity, exercise function, quality of life, and more significant weight loss than the placebo group

Novo Nordisk, for its part, retains core assets (Wegovy, Ozempic and its own pipeline like cagrisema)
By offering semaglutide with no retail price markup, Sesame aims to change that inequity

This study also noted interesting findings concerning sleep
